Migraine and Antiphospholipid Antibodies

Migraine and antiphospholipid antibodies. Cephalalgia 1992:12:69–74. Antiphospholipid antibodies have been detected in patients with transient neurologic symptoms including migraine aura. The role of these antibodies in the pathogenesis of migraine is not fully understood. The available data suggest an association between the migraine-like phenomena and antiphospholipid antibodies, but not between migraine headache and antiphospholipid antibodies. To elucidate the actual role of antiphospholipid antibodies in migraine, prospective, controlled studies are needed.

Download Full-text

Migraine and Antiphospholipid Antibodies: No Association Found in Migraine-Discordant Monozygotic Twins

Cephalalgia ◽

10.1111/j.1468-2982.2008.01646.x ◽

2008 ◽

Vol 28 (10) ◽

pp. 1048-1052 ◽

Cited By ~ 13

Author(s):

FMK Williams ◽

LF Cherkas ◽

ML Bertolaccini ◽

V Murru ◽

GL Surdulescu ◽

...

Keyword(s):

General Population ◽

Antiphospholipid Antibodies ◽

Migraine Headache ◽

Pregnancy Loss ◽

Natural Experiment ◽

Genetic Factors ◽

Monozygotic Twins ◽

Anticardiolipin Antibody ◽

Mz Twins

Migraine headache (with and without aura) is common in the general population and is known to be influenced by genetic factors with heritability estimates between 34-57±. Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by clinical features including venous and arterial thromboses, pregnancy loss and migraine, and by association with antiphospholipid antibodies (aPL). Numerous small studies have investigated whether aPL are associated with migraine in the general population—-with contradictory results. In this study, the question was addressed by studying the prevalence of aPL in members of monozygotic (MZ) twin pairs differing in their migraine status. Such twins provide a unique natural experiment, matched as they are for age, sex and genetic factors, and allow the role of environmental factors, such as aPL, to be determined. Despite 95± power to detect a difference of 0.59 IgG units per litre in anticardiolipin antibody IgG titres, no difference in prevalence of aPL could be detected in migraine-discordant MZ twins.

Download Full-text

Study the biochemical and molecular role of angiotensin converting enzyme in migraine and non-migraine headache

International Journal of Pharmaceutical Research ◽

10.31838/ijpr/2020.12.02.0049 ◽

2020 ◽

Vol 12 (02) ◽

Keyword(s):

Angiotensin Converting Enzyme ◽

Migraine Headache ◽

Converting Enzyme

Download Full-text

The actual role of thrombolytic treatment in central retinal artery occlusion

Archivos de la Sociedad Española de Oftalmología (English Edition) ◽

10.1016/j.oftale.2020.09.006 ◽

2021 ◽

Author(s):

A.R. Allocco ◽

N.E. Quintana ◽

M.G. Magurno

Keyword(s):

Central Retinal Artery Occlusion ◽

Retinal Artery Occlusion ◽

Artery Occlusion ◽

Central Retinal Artery ◽

Thrombolytic Treatment ◽

Actual Role ◽

Retinal Artery

Download Full-text

Role of Tissue Factor in the Pathogenesis of COVID-19 and the Possible Ways to Inhibit It

Clinical and Applied Thrombosis/Hemostasis ◽

10.1177/10760296211003983 ◽

2021 ◽

Vol 27 ◽

pp. 107602962110039

Author(s):

Carlos A. Cañas ◽

Felipe Cañas ◽

Mario Bautista-Vargas ◽

Fabio Bonilla-Abadía

Keyword(s):

Tissue Factor ◽

Proinflammatory Cytokines ◽

Antiphospholipid Antibodies ◽

Therapeutic Strategies ◽

Prothrombotic State ◽

Pulmonary Epithelium ◽

Angiotensin Converting Enzyme 2 ◽

Patients With Heart Failure ◽

Inflammatory Effect

COVID-19 (Coronavirus Disease 2019) is a highly contagious infection and associated with high mortality rates, primarily in elderly; patients with heart failure; high blood pressure; diabetes mellitus; and those who are smokers. These conditions are associated to increase in the level of the pulmonary epithelium expression of angiotensin-converting enzyme 2 (ACE-2), which is a recognized receptor of the S protein of the causative agent SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2). Severe cases are manifested by parenchymal lung involvement with a significant inflammatory response and the development of microvascular thrombosis. Several factors have been involved in developing this prothrombotic state, including the inflammatory reaction itself with the participation of proinflammatory cytokines, endothelial dysfunction/endotheliitis, the presence of antiphospholipid antibodies, and possibly the tissue factor (TF) overexpression. ARS-Cov-19 ACE-2 down-regulation has been associated with an increase in angiotensin 2 (AT2). The action of proinflammatory cytokines, the increase in AT2 and the presence of antiphospholipid antibodies are known factors for TF activation and overexpression. It is very likely that the overexpression of TF in COVID-19 may be related to the pathogenesis of the disease, hence the importance of knowing the aspects related to this protein and the therapeutic strategies that can be derived. Different therapeutic strategies are being built to curb the expression of TF as a therapeutic target for various prothrombotic events; therefore, analyzing this treatment strategy for COVID-19-associated coagulopathy is rational. Medications such as celecoxib, cyclosporine or colchicine can impact on COVID-19, in addition to its anti-inflammatory effect, through inhibition of TF.

Download Full-text

Antiphospholipid Antibodies in Sickle Cell Disease: A Systematic Review and Exploratory Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis ◽

10.1177/10760296211002914 ◽

2021 ◽

Vol 27 ◽

pp. 107602962110029

Author(s):

Mira Merashli ◽

Alessia Arcaro ◽

Maria Graf ◽

Matilde Caruso ◽

Paul R. J. Ames ◽

...

Keyword(s):

Sickle Cell Disease ◽

Sickle Cell ◽

Antiphospholipid Antibodies ◽

Meta Analysis ◽

Age Groups ◽

Anticardiolipin Antibodies ◽

Cell Disease ◽

Pooled Prevalence ◽

The Relationship

The relationship between antiphospholipid antibodies (aPL) and sickle cell disease (SCD) has never been systematically addressed. Our aim was to evaluate potential links between SCD and aPL in all age groups. EMBASE/PubMed was screened from inception to May 2020 and Peto odds ratios for rare events were calculated. The pooled prevalence (PP) of IgG anticardiolipin antibodies (aCL) was higher in individuals with SCD than in controls (27.9% vs 8.7%, P < 0.0001), that of IgM aCL was similar in the two groups (2.9% vs 2.7%); only individuals with SCD were positive for lupus anticoagulant (LA) (7.7% vs 0%, P < 0.0001). The PP of leg ulcers was similar between aPL positive and negative individuals (44% vs 53%) and between patients in acute crisis and stable patients (5.6% vs 7.3%). Reporting of aPL as a binary outcome and not as a titer precluded further interpretation. The results indicate that a prospective case-control study with serial measurements of a panel of aPL in SCD patients might be warranted, in order to understand further the possible pathogenic role of aPL in SCD.

Download Full-text